2025 年 8 月 27 日 公司研究 25Q2 营收承压，海外业务快速增长 ——新产业（300832.SZ）2025 年半年报点评 要点 事件：公司发布 2025 年半年报度报告。2025 年上半年，公司实现营业收入 21.85 亿元，同比减少 1.18%；归母净利润 7.71 亿元，同比减少 14.62%；扣非归母 净利润 7.26 亿元，同比下降 16.33%。其中，2025 年 Q2 实现营收 10.60 亿元， 同比下降 10.88%；归母净利润 3.34 亿元，同比下降 30.06%；扣非归母净利润 3.09 亿元，同比下降 34.00%。 点评： 盈利预测、估值与评级：考虑到集采落地、检验拆套餐等可能对公司带来的持续 影响，我们下调公司 25-27 年的归母净利润预测为 18.76/22.06/25.98 亿元（原 预测值为 19.92 /24.45/29.32 亿元，分别下调 5.8%/9.8%/11.4%），现价对应 25-27 年 PE 为 24/21/17 倍。公司为国内化学发光头部公司，有望充分受益于 进口替代，同时看好公司的海外拓展，继续维持"买入"评级。 风险提示：主营业务单一风 ...

Core Viewpoint - The report from Ping An Securities indicates that New Industry achieved a net profit attributable to shareholders of 771 million yuan in H1 2025, reflecting a year-on-year decrease of 14.62%. The net profit for Q2 alone was 334 million yuan, down 30.06% year-on-year [1] Financial Performance - The revenue growth aligns with expectations, although short-term performance is pressured by domestic market factors such as DRG/DIP reforms and centralized procurement [1] - As of the end of H1 2025, the number of tertiary hospitals served by the company reached 1,835, with a coverage rate of 47.60%, and the coverage rate for top-tier hospitals reached 63.51% [1] Market Strategy - The company focuses on the in vitro diagnostics sector, maintaining a firm development strategy while continuously expanding both domestic and overseas markets, which drives growth [1] - Due to the pressures from centralized procurement and policy environment, the earnings per share (EPS) forecasts for 2025-2027 have been adjusted to 2.44, 3.03, and 3.76 yuan, respectively, down from previous forecasts of 2.69, 3.32, and 4.10 yuan [1] Growth Potential - Despite the adjustments in EPS forecasts, the company has maintained strong installation numbers domestically and internationally, with an increasing proportion of medium and large machines. The centralized procurement is expected to accelerate domestic substitution, which will continue to drive reagent volume growth [1] - The recommendation rating remains "recommended" based on these factors [1]

Investment Rating - The report maintains a "Recommended" rating for the company [1][9]. Core Views - The company's revenue growth aligns with expectations, facing short-term pressure in the domestic market due to DRG/DIP reforms and centralized procurement, while the overseas market shows strong performance [4][5]. - The domestic market revenue for H1 2025 was 1.229 billion yuan, down 12.81% year-on-year, with the domestic reagent business declining by 18.96% due to price drops from inter-provincial alliance procurement and reduced testing volumes [4]. - The overseas market revenue reached 0.952 billion yuan in H1 2025, up 19.57% year-on-year, driven by a 36.86% increase in reagent business due to rising instrument installations [5]. Financial Summary - For H1 2025, the company achieved operating revenue of 2.185 billion yuan, down 1.18% year-on-year, and a net profit of 0.771 billion yuan, down 14.62% year-on-year [3]. - The company projects operating revenues of 4.989 billion yuan, 6.011 billion yuan, and 7.225 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 10.0%, 20.5%, and 20.2% [6][12]. - The net profit is expected to be 1.921 billion yuan, 2.381 billion yuan, and 2.953 billion yuan for the same years, with growth rates of 5.0%, 24.0%, and 24.0% respectively [6][12]. Market Position and Strategy - The company continues to expand its high-end product matrix, with flagship machines leading the market and a total installation of 4,300 units by H1 2025 [8]. - The company has established operations in 14 core countries, enhancing its global brand presence and transitioning to a deeper operational phase in overseas markets [5][8]. - The company is focusing on increasing sales and R&D investments to support long-term growth, despite short-term performance pressures [8].

Core Insights - The economic cooperation between China and ASEAN has become increasingly active, with China's imports and exports to ASEAN reaching 3.67 trillion yuan in the first half of the year, a year-on-year increase of 9.6%, surpassing the overall growth rate of China's goods trade [1] - The completion of the China-ASEAN Free Trade Area 3.0 negotiations is expected to lower the entry barriers for Chinese companies into the ASEAN market, enhance connectivity, and reduce operational costs, ultimately establishing a more resilient regional supply chain [1][2] Economic Cooperation - The China-ASEAN Free Trade Area 3.0 significantly expands the original framework by adding nine new chapters, including digital economy, green economy, and supply chain connectivity, which will facilitate deeper regional cooperation [2] - The completion of the negotiations sends a clear signal of deepening regional cooperation and strengthening connectivity amid rising global protectionism [2] Investment Trends - ASEAN has become a preferred destination for Chinese foreign direct investment (ODI), with a projected growth of 12.6% in 2024 [4] - The region's appeal lies in its proximity to China, lower operational costs, and a young population, providing a substantial consumer market [5] - Chinese investment in ASEAN is transitioning from infrastructure to innovation, with a focus on technology, consumer goods, clean energy, and digital services [5] Financial Needs and Challenges - Chinese companies expanding into ASEAN have evolving financial needs, including understanding local business environments, liquidity management, and risk hedging [8] - Different stages of development present unique challenges, from understanding legal and tax frameworks to maximizing capital efficiency during the investment phase [8] Digital Economy Development - ASEAN's digital economy is projected to reach $1 trillion by 2030, with potential to double if the ASEAN Digital Framework Agreement is successfully implemented [11] - Standard Chartered Bank aims to be a key partner in ASEAN's digital transformation, leveraging its global network and expertise [12] Currency Usage - The use of the renminbi in ASEAN has shown strong growth, with cross-border renminbi settlement volume expected to increase by 35% in 2024 [14] - The establishment of local currency settlement frameworks and the integration of local banks into the renminbi cross-border payment system are enhancing transaction efficiency [15]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2][5][8] Core Views - The company's overall performance declined in the first half of 2025, primarily due to domestic market pressures, with domestic revenue down 12.81% to 12.29 billion yuan. However, overseas business showed strong growth, with revenue increasing by 19.57% to 9.52 billion yuan, driven by a rise in instrument installations and a growing share of overseas revenue [3][4] - The company is focusing on high-end product development, achieving significant market validation. In the domestic market, 774 units of the chemiluminescence immunoassay analyzer were installed, with large machines accounting for 74.81% of installations. The company has also made breakthroughs in small molecule detection, with 14 new products approved for market [4][5] Financial Summary - For the first half of 2025, the company reported revenue of 2.185 billion yuan, a decrease of 1.18%, and a net profit of 771 million yuan, down 14.62%. The second quarter saw revenue of 1.060 billion yuan, down 10.88%, and a net profit of 334 million yuan, down 30.06% [2][3] - The company expects revenue to reach 4.567 billion yuan in 2025, with a slight growth of 0.7%, and net profit to be 1.761 billion yuan, a decrease of 3.7%. The projected earnings per share (EPS) for 2025 is 2.24 yuan [5][10]

医疗器械 国内外高端产品占比持续提升，看好公司海外业务持续快速增长 新产业（300832.SZ） 证券研究报告/公司点评报告 2025 年 08 月 26 日 | 评级： | 买入（维持） | 公司盈利预测及估值 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | 分析师：谢木青 | | 营业收入（百万元） | 3,930 | 4,535 | 5,049 | 5,926 | 6,962 | | | | 增长率 yoy% | 29% | 15% | 11% | 17% | 17% | | 执业证书编号：S0740518010004 | | 归母净利润（百万元） | 1,654 | 1,828 | 1,841 | 2,145 | 2,508 | | Email：xiemq@zts.com.cn | | 增长率 yoy% | 25% | 11% | 1% | 16% | 17% | | | | 每股收益（元） | 2.10 | 2.33 | ...

Core Viewpoint - The company has reported a decline in domestic revenue due to market challenges while achieving growth in overseas markets, driven by strategic innovations and product development [5][6][9]. Group 1: Company Overview - The company focuses on independent innovation and continuous technological advancements to provide high-quality in vitro diagnostic products globally [5]. - The company has not changed its controlling shareholder or actual controller during the reporting period [5]. Group 2: Financial Performance - The company achieved operating revenue of 1.84 billion yuan, a decrease of 1.18% year-on-year, with a total profit of 875 million yuan, down 15.87% year-on-year [9]. - The net profit attributable to shareholders was 771 million yuan, a decrease of 14.62% compared to the previous year [9]. Group 3: Domestic Market Performance - Domestic revenue from in vitro diagnostic services was 1.23 billion yuan, a year-on-year decline of 12.81%, with reagent revenue down 18.96% and instrument revenue up 18.18% [6]. - The company installed 774 units of chemiluminescence immunoassay analyzers, with a 74.81% share of large machines, and served 1,835 tertiary hospitals, achieving a coverage rate of 47.60% [6]. Group 4: International Market Performance - The company established a wholly-owned subsidiary in South Korea and has built operational systems in 14 core countries, enhancing its global brand influence [7]. - Overseas revenue reached 952 million yuan, a year-on-year increase of 19.57%, with reagent business growing by 36.86% [7]. Group 5: Product Development and Sales - The flagship model MAGLUMI X8 has achieved a cumulative installation of 4,300 units, reinforcing the company's leading position in high-end chemiluminescence [8]. - The company has successfully launched the SATLARS T8 automated laboratory line, with a total of 179 lines installed globally [8]. Group 6: Profitability Metrics - The overall gross margin was 68.64%, with instrument gross margin at 26.16%, reflecting a strategic differentiation in product offerings [9].

Core Insights - The company reported a slight decline in revenue and net profit for the first half of 2025, with revenue at 2.185 billion yuan, down 1.18% year-on-year, and net profit at 771 million yuan, down 14.62% year-on-year [1] Financial Performance - The basic earnings per share for the company stood at 0.9814 yuan [1] - The overall gross margin for the company was 68.64%, reflecting a decrease due to the growth in instrument revenue [1] Product Segment Analysis - The gross margin for instrument products was 26.16%, which is a decrease of 3.66 percentage points compared to 2024 [1] - The gross margin for instruments in overseas markets was significantly higher at 38.30% [1] - Despite a slowdown in reagent revenue growth due to domestic centralized procurement policies, the gross margin for both domestic and international reagents remained relatively stable due to optimized production costs and supply chain efficiency [1]

随着公司业务的快速发展，公司及子公司业务涉及美元、欧元等外币结算量 不断上升。当市场汇率出现较大波动时，汇兑损益对公司的经营业绩会造成一定 的影响。为了降低汇率波动对公司业绩的影响，增加公司财务对汇率波动风险的 管控，公司拟与银行等金融机构开展与日常经营需求紧密相关的外汇套期保值业 务，降低汇率波动风险。 深圳市新产业生物医学工程股份有限公司 关于开展外汇套期保值业务的可行性分析报告 一、 开展外汇套期保值业务的目的 交易品种包括远期结售汇、外汇掉期（互换）或混合上述产品特征的外汇衍 生品。 （二） 交易对方 公司选择经有关政府部门批准、具有外汇套期保值业务经营资质的银行等金 融机构开展外汇套期保值业务。公司主要向中国银行、招商银行等商业银行开展 上述外汇套期保值业务。 二、 外汇套期保值业务基本情况 (一) 主要涉及币种及业务品种 公司拟开展的外汇套期保值业务的币种只限于从事公司日常经营业务所使 用的主要结算货币，包括美元、欧元等。 （三） 授权及期限 鉴于外汇套期保值业务与公司的经营密切相关，公司董事会授权总经理审批 日常外汇套期保值业务方案，签署相关协议及文件；由公司财务部门为业务经办 机构，行使外汇套 ...

编制单位：深圳市新产业生物医学工程股份有限公司 单位：万元 法定代表人：饶微 主管会计工作负责人：丁晨柳 会计机构负责人：丁晨柳 | 非经营性 | 资金占用 | 占用方与 | 上市公司核 | 年期初占 2025 | 年 2025 | 月占用 1-6 | 年 2025 | 月占用 1-6 | 年 月 2025 1-6 | 2025 | 年 月末占 6 | 占用形 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 资金占用 | 方名称 | 上市公司的 | 算的会计科 | 用资金余额 | | 累计发生金额（不 | | 资金的利息（如 | 偿还累计发生 | | 用资金余额 | 成原因 | 占用性质 | | | | 关联关系 | 目 | | | 含利息） | | 有） | 金额 | | | | | | 控股股东、实际 控制人及其附 | — | — | — | — | | — | | — | — | | — | — | 非经营性占用 | | 属企业 | — | — | — | — | | ...